My watch list  


Systematic (IUPAC) name
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
CAS number 54350-48-0
ATC code D05BB01
PubChem 3312
DrugBank APRD00966
Chemical data
Formula C23H30O3 
Mol. mass 354.483 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes Oral

Etretinate (trade name Tegison®) is a medication used to treat severe psoriasis. It was removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.


  • Etretinate is a teratogen, and may cause birth defects long after use. Therefore, etretinate should only be used if one is never to get pregnant.
  • Etretinate should be avoided in children, as it may interfere with growth of bone.

Side effects

  • Hepatitis
  • Pseudotumor cerebri

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Etretinate". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE